[1] 中华医学会感染病学分会, 中华医学会肝病学分会.慢性乙型肝炎临床治愈(功能性治愈)专家共识.中华肝脏病杂志, 2019, 27:594-603.
[2] Tian T, Song C, Jiang L, et al. Hepatitis B virus infection and the risk of cancer among the Chinese population. Int J Cancer, 2020, 147:3075-3084.
[3] Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther, 2019, 50: 1037-1048.
[4] Song C, Lv J, Liu Y, et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw Open, 2019, 2: e195718.
[5] Kamiza AB, Su FH, Wang WC, et al. Chronic hepatitis infection is associated with extrahepatic cancer development: a nationwide population-based study in Taiwan. BMC Cancer, 2016, 16: 861.
[6] 郑昕, 刘嘉, 吴珺, 等.免疫控制与慢性乙型肝炎功能性治愈的进展与挑战.临床肝胆病杂志, 2020, 36:961-964.
[7] Chevaliez S, Hézode C, Bahrami S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. Hepatol, 2013, 58:676-683.
[8] Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol, 2000, 74:4165-4173.
[9] Wieland SF, Eustaquio A, Whitten-Bauer C, et al.Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA, 2005, 102:9913-9917.
[10] Uprichard SL, Wieland SF, Althage A, et al. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci USA, 2003, 100:1310-1315.
[11] Xu C, Guo H, Pan XB, et al. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus.J Virol, 2010, 84:9332-9340.
[12] Belloni L, Allweiss L, Guerrieri F, et al. IFNalpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest, 2012, 122:529-537.
[13] Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial .Lancet, 2005, 365: 123-129.
[14] Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol. 2013, 58:205-209.
[15] 程海军, 成军, 王兰舟, 等.恩替卡韦治疗慢性乙型肝炎患者血清IL-4 和 IL-10 水平变化.中西医结合肝病杂志, 2014, 24:114-115.
[16] 张如幸.恩替卡韦联合聚乙二醇干扰素α-2a对慢性乙型肝炎患者血清IFN-γ、IL-10水平及肝纤维化的影响.临床医学工程, 2020, 27:293-294.
[17] Chan HLY, Chan FWS, Hui AJ, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. J Viral Hepat, 2019, 26:126-135.
[18] Han MF, Wu D, Tan DM, et al.Combination/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF en-hanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients(the Anchor A study):An interim analysis.Hepatology, 2017, 29.
[19] Li GJ, Yu YQ, Chen SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother, 2015, 59:4121-4128.
[20] 胡鹏, 尚佳, 张文宏, 等.核苷(酸)类似物治疗部分应答的乙型肝炎患者通过聚乙二醇干扰素α-2a治疗获得HBsAg消失:New Switch研究.中华肝脏病志, 2018, 26:756-764.
[21] Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352:2682-2695.
[22] Zhu S, Zhang H, Dong Y, et al.Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol, 2018, 68:1123-1128.
[23] 张希顺, 申雪粉, 王雷, 等.恩替卡韦应答不佳慢性乙型肝炎患者联合干扰素治疗效果观察.河北医药, 2019, 41:2146-2149, 2153.
[24] 岳伟, 袁宏, 毛小荣, 等. 不同策略治疗 rtN236T 位点变异的 HBeAg阳性慢性乙型肝炎的疗效观察.中华肝脏病杂志, 2013, 21:184-188.
[25] 陈新月, 柳雅立.干扰素与核苷(酸)类似物联合治疗开创HBsAg转阴之路.传染病信息, 2015, 28:262-265.
[26] Lu JF, Zhang SB, Liu YL et al. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.Liver Int, 2015, 35: 1692-1699.
[27] Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis, 2017, 23:765-772.
[28] Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology, 2017, 66:1058-1066.
[29] Zeng QL, Yu ZJ, Shang J, et al. Short-term peginterferon-induced high functional cure rate in inactive chronic hepatitis B virus carriers with low surface antigen levels. Open Forum Infect Dis, 2020, 7:ofaa208.
[30] Lee JH, Lee YB, Cho EJ, et al. Entecavir plus pegylated interferon and sequential HBV vaccination increases HBsAg sseroclearance: a randomized controlled proof-of-concept study. Clin Infect Dis, 2020.
[31] 江海洋, 顾生旺, 刘欢, 等.基于1 783例慢性乙型肝炎患者长期随访的结果对大幅度提高其临床治愈的思考.肝脏, 2020, 25:169-172.
[32] 江水清, 王瑜, 王健.IFN对慢性乙肝患者PBMC内HBV-DNA的阴转作用.现代预防医学, 2007, 34:1819-1822. |
